Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 4NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Immunoglobulin Light-chain Amyloidosis 1Hematologic Diseases 1

Interventions

Melphalan 4sargramostim 3Peripheral Blood Stem Cell Transplantation 3Cyclophosphamide 3Interferon-alpha 2Filgrastim 2Dexamethasone 2Carboplatin 2Calcium Dobesilate 24'-deoxy-4'-iododoxorubicin 2venetoclax 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1X-Rays 1Sunitinib 1Specimen Handling 1Radiotherapy 1Pharmacogenomic Testing 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Ketamine 1Interleukin-12 Subunit p35 1Imatinib Mesylate 1Ifosfamide 1Docetaxel 1Decitabine 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Immunoglobulin Light-chain Amyloidosis × ixazomib × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡